Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas

Mateusz Opyrchal, Ileana Aderca, Evanthia Galanis

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

40 Scopus citations

Abstract

Despite many advances in cancer therapy, metastatic disease continues to be incurable in the majority of cancer patients. There ia an need for more efficient and less toxic treatments is this setting. Oncolytic virotherapy represents a novel promising direction in the treatment of cancer. Based on preclinical and clinical data, combination with standard chemotherapy has the potential to further increase the antitumor activity of oncolytic virotherapy in a synergistic manner. We present the design of a phase I clinical trial combining intratumoral injections of the oncolytic adenovirus ONYX-015 with systemic chemotherapy in patients with advanced sarcomas.

Original languageEnglish
Title of host publicationGene Therapy of Cancer
Subtitle of host publicationMethods and Protocols
EditorsWolfgang Walther, Ulrike Stein
Pages705-717
Number of pages13
DOIs
StatePublished - 2009

Publication series

NameMethods in Molecular Biology
Volume542
ISSN (Print)1064-3745

Keywords

  • Cisplatin chemotherapy
  • ONYX-015
  • doxorubicin
  • mitomycin-C
  • oncolytic adenovirus
  • sarcomas

Fingerprint

Dive into the research topics of 'Phase i clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas'. Together they form a unique fingerprint.

Cite this